|
Thoughts
Feb 22, 2016 2:07:06 GMT -5
via mobile
Post by kdaddyfresh2000 on Feb 22, 2016 2:07:06 GMT -5
What are people's thoughts on the remaining board and management team's ability and drive to turn Mannkind around?
|
|
|
Post by als57 on Feb 22, 2016 7:08:45 GMT -5
A pitiful bunch of nomads, wondering the wiles of big Pharma, being led by Matt with "hacking Hakan" as a camp follower!
|
|
|
Post by agedhippie on Feb 22, 2016 7:36:33 GMT -5
As with most things I think it's a trade off. The management team lack turnaround experience, this is Matt's first CEO position, they don't have a separate CFO (Matt is still CFO), and their performance to date is awful. In their defense they know the product inside out, and there is a limit to what they can do with their current cash and situation. Really though they need a strong outsider with pharma experience to be the CEO and drive this.
|
|
|
Post by bioexec25 on Feb 22, 2016 7:53:20 GMT -5
They are technically & operationally competent for the most part. They are not even close to being even average deal makers imo but hopefully they are getting counsel. They clearly do not have commercialization expertise which is critically needed, Comm Ops largest gap to fill at this point, internally or with a partnership.
|
|
|
Post by rvc on Feb 22, 2016 7:56:21 GMT -5
They had a strong insider from Pharma in Desisto but he looked at the situation and bailed out. I don't buy for a second that suddenly a conflict of interest came up(I would have liked to have heard Matt address Desisto's resignation when he took investor questions, but he didn't). It seems to me that it was a convenient excuse to let him walk away with MNKD saving face. I have absolutely no confident in Matt, and frankly, I think he was only made the CEO because no credible pharma leader would touch this with a ten foot pole. Sadly, it seems it's just a matter of time before BK, probably by this summer.
|
|
|
Post by dictatorsaurus on Feb 22, 2016 8:17:45 GMT -5
We have the most revolutionary treatment ever invented for Diabetes and the SP is at 99 cents.
There's your answer.
|
|
|
Post by yash on Feb 22, 2016 8:23:30 GMT -5
Institutional holding increased and currently stands at 25.93 that includes GS. Al has put all his money and still in. Management is so incompetent because they could not read the mind of SNY that they will sandbag and drop off Afrezza after one year.
Institutions and Al is just happy to loose all their money as "it's just a matter of time before BK, probably by this summer." Wow
"Sorry to be sarcastic"
|
|
|
Post by esstan2001 on Feb 22, 2016 8:23:37 GMT -5
SNY fixed ratio basal- Lixilan combo NDA accepted by FDA this am. This is what they want to focus on to expand their D franchise. Isn't it going the wrong way to fix the basal to prandial ratio (and this one size all approach is being done in the name of convenience?)?
Crazy, or I must be (going there)
|
|
|
Post by yash on Feb 22, 2016 8:26:23 GMT -5
We have the most revolutionary treatment ever invented for Diabetes and the SP is at 99 cents. There's your answer. Excellent reply
|
|
Deleted
Deleted Member
Posts: 0
|
Thoughts
Feb 22, 2016 8:49:11 GMT -5
via mobile
Post by Deleted on Feb 22, 2016 8:49:11 GMT -5
SNY fixed ratio basal- Lixilan combo NDA accepted by FDA this am. This is what they want to focus on to expand their D franchise. Isn't it going the wrong way to fix the basal to prandial ratio (and this one size all approach is being done in the name of convenience?)? Crazy, or I must be (going there) Decision is not until August 2016 . Only the NDA is accepted as of today
|
|
|
Post by peppy on Feb 22, 2016 8:56:17 GMT -5
SNY fixed ratio basal- Lixilan combo NDA accepted by FDA this am. This is what they want to focus on to expand their D franchise. Isn't it going the wrong way to fix the basal to prandial ratio (and this one size all approach is being done in the name of convenience?)? Crazy, or I must be (going there) www.prnewswire.com/news-releases/fda-accepts-sanofi-new-drug-application-for-once-daily-fixed-ratio-combination-of-insulin-glargine-and-lixisenatide-300223605.html
fixed-ratio combination of basal insulin glargine 100 Units/mL and GLP-1 receptor agonist lixisenatide for the treatment of adults with type 2 diabetes.
------------------------------------------------------------------------------------------------------------------------------------------------------ If I have this correct, Afrezza performs the same signaling to the liver that GLP-1 does. Both signal the liver to stop making and putting glucose into the blood stream. Afrezza sends the signal to the liver through the large blood insulin bolus it gives. The phase 1.
Interesting gig. screencast.com/t/AhnFhHunq
A strange conflict of interest?
regarding thought on management. I will know more april 5th.
|
|
|
Post by yash on Feb 22, 2016 9:24:54 GMT -5
In response to the topic on management
College dropout. Fired tech executive. Unsuccessful businessman.
The company he founded, was fired from, and then returned to has gone from also-ran to technology industry leader.
Steve Jobs will always be best known for his incredible success in guiding Apple Inc. and transforming the entire consumer computer and phone industry. But he’ll also be remembered fondly as the poster child for how making mistakes — and even failing — can sometimes end up being the best thing that ever happens to you.
|
|
|
Post by prosper on Feb 22, 2016 9:25:38 GMT -5
Have all of you really googled Ken, our new Chairman? This man is a turnaround expert and really well connected at levels way above anyone else on the board.
|
|
|
Post by madog365 on Feb 22, 2016 9:51:07 GMT -5
From LA Business Journal: Ahmed Enany, president and chief executive of Southern California Biomedical Council, a trade organization, described the leadership transition as “a good opportunity for MannKind to explore new growth strategies such as mergers and acquisitions,” adding that Kresa is a person who “could steer the ship in the right direction.” Enany also noted that Mann, who serves as chairman emeritus of the SoCalBio trade group according to its website, had both philanthropic and business projects in the works, so the move would allow him to put his time into those other pursuits. Mann was the Business Journal´s Los Angeles Business Person of the Year in 2003, while Kresa received the honor in 2002. www.labusinessjournal.com/news/2016/feb/19/alfred-mann-steps-down-chairman-mannkind-corp/
|
|
|
Post by bradleysbest on Feb 22, 2016 10:09:38 GMT -5
Have all of you really googled Ken, our new Chairman? This man is a turnaround expert and really well connected at levels way above anyone else on the board. Impressive credentials & background for sure. Now we need him to produce. No time to waste & I hope MNKD is ready to rock & roll April 5th!
|
|